ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 78 filers reported holding ALX ONCOLOGY HLDGS INC in Q3 2023. The put-call ratio across all filers is 0.07 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,159,787 | -36.1% | 1,283,289 | 0.0% | 0.29% | -20.8% |
| Q2 2023 | $9,637,500 | +263.2% | 1,283,289 | +118.6% | 0.37% | +221.7% |
| Q1 2023 | $2,653,136 | -61.2% | 586,977 | -3.4% | 0.12% | -58.9% |
| Q4 2022 | $6,846,187 | -4.9% | 607,470 | -19.2% | 0.28% | +0.4% |
| Q3 2022 | $7,198,000 | +16.0% | 752,097 | -1.9% | 0.28% | +17.7% |
| Q2 2022 | $6,203,000 | -52.5% | 766,797 | -0.7% | 0.24% | -41.8% |
| Q1 2022 | $13,054,000 | -22.3% | 772,397 | -1.2% | 0.41% | +6.5% |
| Q4 2021 | $16,807,000 | -73.7% | 782,097 | -9.5% | 0.38% | -65.7% |
| Q3 2021 | $63,847,000 | +27.7% | 864,435 | -5.4% | 1.11% | +50.5% |
| Q2 2021 | $49,979,000 | -30.7% | 914,035 | -6.6% | 0.74% | -27.2% |
| Q1 2021 | $72,162,000 | -12.8% | 978,600 | +1.9% | 1.02% | +1.4% |
| Q4 2020 | $82,786,000 | +438.4% | 960,400 | +135.7% | 1.00% | +255.3% |
| Q3 2020 | $15,375,000 | – | 407,400 | – | 0.28% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |